Magnetic pulses detect thinking problems
- Trial ID
- NCT06835595
- Official Title
- Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)
- Goal
- Magnetic pulses detect thinking problems
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
- Study Type
- INTERVENTIONAL
- Enrollment
- 52 participants
- Conditions
- Parkinson Disease
- Interventions
- Transcranial Magnetic Stimulation
Plain-Language Summary
The goal is to find noninvasive brain measures that signal cognitive impairment in Parkinson's, so thinking problems can be detected or tracked earlier and more reliably. The approach uses transcranial magnetic stimulation, which delivers brief magnetic pulses to the scalp to probe cortical excitability, connectivity, and plasticity, recording responses that might link to memory and attention changes while participants also get neuropsychological testing. Tests are done while people remain on their usual antiparkinsonian medications, kept stable for at least four weeks, so results reflect typical treatment effects. Adults 18 and older with idiopathic PD who can complete neuropsychological testing and give informed consent are eligible, while people with dementia by MDS criteria, implanted metal or electronic devices, a history of seizures, pregnancy, or certain seizure‑risk medications are excluded.
Locations
- SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Friuli Venezia Giulia, Italy
- UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige, Sterzing, Trentino-Alto Adige, Italy
- UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Trentino-Alto Adige, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial Magnetic Stimulation. The goal is to find noninvasive brain measures that signal cognitive impairment in Parkinson's, so thinking problems can be detected or tracked earlier and more reliably. The approach uses transcranial magnetic stimulation, which delivers brief magnetic pulses to the scalp to probe cortical excitability, connectivity, and plasticity, recording responses that might link to memory and attention changes while participants also get neuropsychological testing. Tests are done while people remain on their usual antiparkinsonian medications, kept stable for at least four weeks, so results reflect typical treatment effects. Adults 18 and older with idiopathic PD who can complete neuropsychological testing and give informed consent are eligible, while people with dementia by MDS criteria, implanted metal or electronic devices, a history of seizures, pregnancy, or certain seizure‑risk medications are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 4 months.